Novo Nordisk Annual Report 6-K Prepared by Imprima
Novo posts strong performance, but US pricing pressure grows | pharmaphorum
IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes - ScienceDirect
Novo Nordisk and Sanofi diabetes combo drugs receive US recommendation
Ideglira (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Combination of Novo Nordisk's Insulin degludec and Victoza Provides Synergistic Benefits in Late-Stage Trial
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients
Positive Phase 3b study resutls for Xultophy announced
New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes
Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in
The clinical benefits of IDegLira in DUAL VII were achieved while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy - Media Centre | EASD
Novo Nordisk debuts diabetes combo in Mexico - PMLiVE
Physicians' real-world experience with IDegLira: results of a European survey | BMJ Open Diabetes Research & Care
IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy – topic of research paper in Clinical medicine. Download scholarly article PDF and read for
Dosificación, Titulación y Aplicación de iDegLira - Novo Nordisk
Presentan en México IDeglira para tratar la diabetes tipo 2 – Mundodehoy.com
New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes
ADA 2014: New data on Novo Nordisk's IDegLira and Victoza
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes | Drugs
REMIT-iDegLira - Research Studies - PHRI - Population Health Research Institute of Canada
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes | Drugs
Novo Nordisk's GLP-1/insulin combination, Xultophy, Moves One Step Closer to Approval in Europe
US approval for Novo Nordisk's Xultophy/IDegLira as diabetes battle hots up
Overview of studies design evaluating the efficacy of iDegLira and... | Download Scientific Diagram
Novo Nordisk invests $60 million in expansion of Kalundborg site
